NBIX vs VRTX
Neurocrine Biosciences vs Vertex Pharmaceuticals — AI-powered side-by-side comparison
NBIX
Neurocrine Biosciences
63
Buy
VS
VRTX
Vertex Pharmaceuticals
67
Buy
| Metric | NBIX | VRTX |
|---|
| AI Score |
63
|
67
|
| Price |
$163.26
|
$496.21
|
| P/E Ratio |
23.18×
|
28.64×
|
| ROE |
14.7%
|
21.2%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.0%
|
86.0%
|
| Debt / Equity |
0.11×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
37.5
|
66.6
|
| Beta |
0.386
|
0.292
|
| Expected Upside |
—
|
+2.3%
|
AI Committee View
Current Innellis committee reasoning for NBIX versus VRTX.
VRTX leads by 4 points.
VRTX scores 67/100 (Buy) versus NBIX at 63/100 (Buy).
NBIX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk
VRTX Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock. The main limiting factor is p/e of 29.0 is moderate-to-rich. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 23.3% shows genuine earnings power backing the valuation — Value
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 29.0 is moderate-to-rich — Value
- Price-to-book of 6.2x prices in significant intangible value — Value
- Price trading above the upper Bollinger Band -- stretched — Technical